2023
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials
Guptill J, Benatar M, Granit V, Habib A, Howard J, Barnett-Tapia C, Nowak R, Lee I, Ruzhansky K, Dimachkie M, Cutter G, Kaminski H, Group F. Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials. Neurology 2023, 101: 442-451. PMID: 37076302, PMCID: PMC10491448, DOI: 10.1212/wnl.0000000000207278.Peer-Reviewed Original ResearchActivities of Daily LivingClinical Trials as TopicHumansMyasthenia GravisOutcome Assessment, Health CareQuality of Life
2020
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic
Group I, Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard J, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak R. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. Journal Of The Neurological Sciences 2020, 412: 116803. PMID: 32247193, PMCID: PMC7105910, DOI: 10.1016/j.jns.2020.116803.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusClinical Trials as TopicCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDisease ManagementDisease SusceptibilityHumansImmunoglobulins, IntravenousImmunologic FactorsImmunosuppressive AgentsImmunotherapyLambert-Eaton Myasthenic SyndromeMyasthenia GravisPandemicsPlasma ExchangePneumonia, ViralSARS-CoV-2Vaccines